Three cancer drugs recommended by NICE

29 July 2010

Capecitabine (Xeloda; Roche), gefitinib (Iressa; AstraZeneca) and rituximab (MabThera; Roche) have all been recommended by the National Institute for Health and Clinical Excellence in final guidance.

Capecitabine is recommended, in combination with a platinum-based regimen, for the first-line treatment of inoperable advanced gastric cancer.

More

Back to Main Page